Amgen is back in court and this time it s suing FDA. Amgen filed a complaint, posted on FDA Law Blog , on May 25, 2017 after FDA denied the company six months of pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA), for its secondary hyperparathyroidism treatment SensiOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.